Beyond antigens and adjuvants: formulating future vaccines

TitleBeyond antigens and adjuvants: formulating future vaccines
Publication TypeJournal Article
Year of Publication2016
AuthorsMoyer, TJ, Zmolek, AC, Irvine, DJ
JournalJournal of Clinical Investigation
Pagination799 - 808
Date Published2016/03//
ISBN Number0021-9738
Keywordsantibody-responses, b-cells, dendritic cell subsets, immune-response, in-vivo, lymph-node, nanoparticle vaccines, protein antigen, size-dependent immunogenicity, toll-like receptors

The need to optimize vaccine potency while minimizing toxicity in healthy recipients has motivated studies of the formulation of vaccines to control how, when, and where antigens and adjuvants encounter immune cells and other cells/tissues following administration. An effective subunit vaccine must traffic to lymph nodes (LNs), activate both the innate and adaptive arms of the immune system, and persist for a sufficient time to promote a mature immune response. Here, we review approaches to tailor these three aspects of vaccine function through optimized formulations. Traditional vaccine adjuvants activate innate immune cells, promote cell-mediated transport of antigen to lymphoid tissues, and promote antigen retention in LNs. Recent studies using nanoparticles and other lymphatic-targeting strategies suggest that direct targeting of antigens and adjuvant compounds to LNs can also enhance vaccine potency without sacrificing safety. The use of formulations to regulate biodistribution and promote antigen and inflammatory cue co-uptake in immune cells may be important for next-generation molecular adjuvants. Finally, strategies to program vaccine kinetics through novel formulation and delivery strategies provide another means to enhance immune responses independent of the choice of adjuvant. These technologies offer the prospect of enhanced efficacy while maintaining high safety profiles necessary for successful vaccines.

Short TitleJ. Clin. Invest.